Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GC1118
BIOLOGICAL
2 trials
Sponsors
Green Cross Corporation
, Samsung Medical Center
Conditions
Colorectal Cancer
EGFR Amplification
Gastric Cancer
Glioblastoma, Adult
Neoplasm Metastasis
Phase 1
Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
NCT02352571
Green Cross Corporation
Colorectal Cancer, Gastric Cancer, Neoplasm Metastasis
Start: 2015-01-31
End: 2017-06-30
Target: 72
Updated: 2016-07-06
Phase 2
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Completed
NCT03618667
Samsung Medical Center
EGFR Amplification, Glioblastoma, Adult
Start: 2018-01-22
End: 2022-04-28
Updated: 2023-05-12
Related Papers
A first-in-human phase I study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer
Annals of Oncology
2018-10-01
A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
Journal of Clinical Oncology
2016-05-20
1 citations